Cargando…
Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer
AIMS: Compare lurbinectedin versus other second-line (2L) small-cell lung cancer (SCLC) treatments. METHODS: An unanchored matching-adjusted indirect comparison connected the platinum-sensitive SCLC cohort of a single-arm lurbinectedin trial to a network of three randomized controlled trials (oral a...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Becaris Publishing Ltd
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402758/ https://www.ncbi.nlm.nih.gov/pubmed/37079341 http://dx.doi.org/10.57264/cer-2022-0098 |
_version_ | 1785084911981428736 |
---|---|
author | Hanvesakul, Raj Rengarajan, Badri Naveh, Navit Boccuti, Anne Park, Julie E Adeyemi, Adekemi Caisip, Clyde Jansen, Jeroen P Wilson, Florence R |
author_facet | Hanvesakul, Raj Rengarajan, Badri Naveh, Navit Boccuti, Anne Park, Julie E Adeyemi, Adekemi Caisip, Clyde Jansen, Jeroen P Wilson, Florence R |
author_sort | Hanvesakul, Raj |
collection | PubMed |
description | AIMS: Compare lurbinectedin versus other second-line (2L) small-cell lung cancer (SCLC) treatments. METHODS: An unanchored matching-adjusted indirect comparison connected the platinum-sensitive SCLC cohort of a single-arm lurbinectedin trial to a network of three randomized controlled trials (oral and intravenous [IV] topotecan, and platinum re-challenge) identified by systematic literature review. Network meta-analysis methods estimated relative treatment effects. RESULTS: In platinum-sensitive patients, lurbinectedin demonstrated a survival benefit and favorable safety profile versus oral and IV topotecan and platinum re-challenge (overall survival, hazard ratio [HR]: 0.43; 95% credible interval [CrI]: 0.27, 0.67; HR: 0.43; 95% CrI: 0.26, 0.70; HR: 0.42; 95% CrI: 0.30, 0.58 respectively). CONCLUSION: Lurbinectedin showed a robust survival benefit and favorable safety versus other SCLC treatments in 2L platinum-sensitive SCLC. |
format | Online Article Text |
id | pubmed-10402758 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Becaris Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-104027582023-08-11 Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer Hanvesakul, Raj Rengarajan, Badri Naveh, Navit Boccuti, Anne Park, Julie E Adeyemi, Adekemi Caisip, Clyde Jansen, Jeroen P Wilson, Florence R J Comp Eff Res Research Article AIMS: Compare lurbinectedin versus other second-line (2L) small-cell lung cancer (SCLC) treatments. METHODS: An unanchored matching-adjusted indirect comparison connected the platinum-sensitive SCLC cohort of a single-arm lurbinectedin trial to a network of three randomized controlled trials (oral and intravenous [IV] topotecan, and platinum re-challenge) identified by systematic literature review. Network meta-analysis methods estimated relative treatment effects. RESULTS: In platinum-sensitive patients, lurbinectedin demonstrated a survival benefit and favorable safety profile versus oral and IV topotecan and platinum re-challenge (overall survival, hazard ratio [HR]: 0.43; 95% credible interval [CrI]: 0.27, 0.67; HR: 0.43; 95% CrI: 0.26, 0.70; HR: 0.42; 95% CrI: 0.30, 0.58 respectively). CONCLUSION: Lurbinectedin showed a robust survival benefit and favorable safety versus other SCLC treatments in 2L platinum-sensitive SCLC. Becaris Publishing Ltd 2023-04-20 /pmc/articles/PMC10402758/ /pubmed/37079341 http://dx.doi.org/10.57264/cer-2022-0098 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License (https://creativecommons.org/licenses/by-nc-nd/4.0/) |
spellingShingle | Research Article Hanvesakul, Raj Rengarajan, Badri Naveh, Navit Boccuti, Anne Park, Julie E Adeyemi, Adekemi Caisip, Clyde Jansen, Jeroen P Wilson, Florence R Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer |
title | Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer |
title_full | Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer |
title_fullStr | Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer |
title_full_unstemmed | Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer |
title_short | Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer |
title_sort | indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402758/ https://www.ncbi.nlm.nih.gov/pubmed/37079341 http://dx.doi.org/10.57264/cer-2022-0098 |
work_keys_str_mv | AT hanvesakulraj indirecttreatmentcomparisonoflurbinectedinversusothersecondlinetreatmentsforsmallcelllungcancer AT rengarajanbadri indirecttreatmentcomparisonoflurbinectedinversusothersecondlinetreatmentsforsmallcelllungcancer AT navehnavit indirecttreatmentcomparisonoflurbinectedinversusothersecondlinetreatmentsforsmallcelllungcancer AT boccutianne indirecttreatmentcomparisonoflurbinectedinversusothersecondlinetreatmentsforsmallcelllungcancer AT parkjuliee indirecttreatmentcomparisonoflurbinectedinversusothersecondlinetreatmentsforsmallcelllungcancer AT adeyemiadekemi indirecttreatmentcomparisonoflurbinectedinversusothersecondlinetreatmentsforsmallcelllungcancer AT caisipclyde indirecttreatmentcomparisonoflurbinectedinversusothersecondlinetreatmentsforsmallcelllungcancer AT jansenjeroenp indirecttreatmentcomparisonoflurbinectedinversusothersecondlinetreatmentsforsmallcelllungcancer AT wilsonflorencer indirecttreatmentcomparisonoflurbinectedinversusothersecondlinetreatmentsforsmallcelllungcancer |